What Is Sanghuang? Korea's Cancer-Fighting Mushroom

Emerging and Specialty Mushrooms

3 human datasets in a literature otherwise built entirely from cells and mice — and none of the three tested sanghuang as a cancer treatment

Sanghuang has one of the deepest preclinical anti-cancer records of any medicinal mushroom, spanning breast, prostate, colon, liver and lung models. In humans it has been tested three times: two immune-function trials in healthy adults from a single Korean research group, and one retrospective analysis in pancreatic cancer patients. No randomised trial has tested it against cancer.

Sliva, Experimental and Therapeutic Medicine, 2010; Ku et al., Medicine, 2022; Han et al., Journal of Microbiology, 2016

Preclinical

the ceiling of every cancer finding attributed to sanghuang

2 lineages

sold under one market name — and Korea's registered cultivars are not the lineage the research is named after

NK activity

the single endpoint that reached significance in the larger of the two human trials

Sliva, Experimental and Therapeutic Medicine, 2010; Ku et al., Medicine, 2022; Han et al., Journal of Microbiology, 2016

View as image ↗

Sanghuang is not a household name in Western supplement aisles, but it is one of the most extensively studied anti-cancer mushrooms in Korean, Chinese and Japanese biomedical research. A 2010 review described it as a candidate for alternative cancer therapy, summarising activity across multiple tumour types and noting a handful of uncontrolled case reports of tumour regression.^[2]

That reputation is real, and it is also the source of the confusion. Two things are true at once: the preclinical record is genuinely large, and not one cancer finding in it has been tested against a cancer outcome in a randomised human trial. The gap between those two facts is where most sanghuang marketing lives.

There is a second problem underneath the first. "Sanghuang" is not a species — it is a traditional category name used across Korea and China, and the organism it refers to depends on who is speaking. Most of the research carries the name Phellinus linteus, but a 2016 phylogenetic study found that the sanghuang varieties formally registered in Korea group with a different species entirely.^[1] For the full species breakdown, see Sanghuang vs. Meshima: Different Species, Different Research.

This article is the overview: what sanghuang is biologically, what the preclinical research found, what the three human datasets actually measured, and how to read a supplement label given that the name on the jar may not match the name on the papers.

What Sanghuang Is: The Bracket Fungus Behind the Research

The mushrooms called sanghuang are bracket fungi in the family Hymenochaetaceae. Unlike the cap-and-stem mushrooms most people picture, they grow as woody, shelf-like projections from tree trunks — on mulberry, fig, oak and other broadleaf hosts across East and Southeast Asia. The fruiting body is brown to reddish-brown on the upper surface, with small, dense pores underneath.

The Chinese name is the clearest guide to the tradition's original meaning: 桑黄, from 桑 (sang, mulberry) and 黄 (huang, yellow) — the yellow bracket that grows on mulberry. The Korean sanghwang shares the same characters. In both traditions the mushroom appears in classical medical texts, used for immunity, inflammation and what those texts describe as tumours.

Commercial cultivation developed in Korea through the latter part of the twentieth century, and that cultivation is what drove the modern research base. By the 1990s Korean laboratories were characterising the compounds responsible for the activity traditional medicine had attributed to the mushroom. Two compound classes dominate the literature: polysaccharides, particularly protein-bound and acidic fractions, which carry most of the immune and anti-tumour findings; and phenolic compounds, principally hispidin and hispolon, which are characteristic of this group of fungi. The compound-specific research is covered in Sanghuang: Korea and China's Prized Anti-Cancer Mushroom and Its Hispidin Content.

The Species Problem: The Name on the Papers Is Not Reliably the Name in the Jar

This is the single most important thing to understand about sanghuang, and it is the part most product pages omit.

For decades, essentially the entire English-language research literature was published under one binomial: Phellinus linteus. That created the appearance of a unified evidence base. Two developments in 2016 complicated it.

First, a taxonomic revision split the Inonotus linteus complex into new genera, erecting Sanghuangporus and Tropicoporus. The organism published as Phellinus linteus became Tropicoporus linteus, while the mulberry-associated species central to the Chinese tradition — including Sanghuangporus sanghuang — moved to the new Sanghuangporus genus.

Second, and more consequentially for anyone buying a supplement, Han and colleagues asked a direct question: what species is Korea actually cultivating and selling as sanghuang?

The paper that reframes the whole category

Han et al. (2016) · Journal of Microbiology

Population

74 strains from the Phellinus linteus–baumii complex, including parental strains of sanghuang varieties registered with the Korea Seed & Variety Service

Intervention

Phylogenetic analysis of ITS nuclear ribosomal DNA sequences

Comparator

Reference sequences across the allied species in the complex

Finding

The registered Korean sanghuang cultivars — ASI 26046 (Corea sanghuang), 26114 (Boolro) and 26115 (HK 1-ho) — grouped with Sanghuangporus sanghuang, not with Phellinus linteus, despite the Korean research and supplement trade using the P. linteus name.

narrow-scope This is a nomenclature and identity finding, not a biological-activity finding. It does not show that the extracts behave differently — only that the name on a paper cannot be assumed to describe the organism in a product.

Han et al., Journal of Microbiology, 2016

The implication is worth stating plainly, because it inverts the tidy story usually told about this mushroom. The common framing — "Korean sanghuang is Phellinus linteus, Chinese sanghuang is Sanghuangporus" — does not survive contact with the phylogeny. Korea's registered cultivars sit on the Sanghuangporus side, even though Korean research and Korean marketing both use the P. linteus name.^[1]

Label → Taxon → Evidence

What Each “Sanghuang” Name Actually Refers To

A supplement label, a research nameplate, and an accepted species name are three different things. Reading each row left to right shows where they line up and where they come apart. The second row is the one that surprises people: the cultivars Korea registers and sells as sanghuang group with Sanghuangporus sanghuang, while the Korean research program that made the mushroom famous is published under Phellinus linteus.

Name you encounter

Accepted taxon (post-2016)

What research exists under it

Meshimaメシマコブ

Japanese supplement trade name

Tropicoporus linteus

formerly Phellinus linteus

50 indexed studies, 1996–2024, nearly all published under the name "Phellinus linteus"[2]

Name tracks the research

Sanghuang상황

Korean registered cultivars

Sanghuangporus sanghuang

per phylogeny of 74 strains

Cultivated material groups with S. sanghuang — not with the P. linteus nameplate the research carries[1]

Name and material diverge

Sanghuang桑黄

Chinese traditional term

Sanghuangporus sanghuang

mulberry-associated

Exactly one indexed study published under a Sanghuangporus binomial[3]

Thin evidence base

Phellinus baumii

still printed on labels

Sanghuangporus baumii

recombined in 2016

Label name predates the 2016 genus split; no separate indexed cancer literature under the current binomial

Thin evidence base

Phellinus igniarius

label and older literature

Often Sanghuangporus vaninii

P. igniarius s.s. is a separate species

Name used loosely across two different organisms; check the strain, not the binomial

Name and material diverge

The practical consequence

A jar labelled only “sanghuang” tells you nothing about which of these organisms is inside. A jar labelled Phellinus linteus tells you which literature the seller is pointing at — but not, on its own, which species was grown. The only label that resolves the ambiguity is a current binomial plus a named strain.

Study counts are of this library’s indexed corpus, not of all literature worldwide — a substantial Chinese- and Korean-language body of work sits outside English-language indexing. Nothing in this map is a claim that any of these mushrooms treats disease.

Taxonomy per Zhou et al., Fungal Diversity, 2016; rows from refs [1]–[3]

None of this invalidates the research. The experiments found what they found, in whatever organism the investigators actually grew. What it changes is the confidence with which a reader can assume that two papers sharing a binomial studied the same fungus — or that a capsule matches either one.

How the Confusion Accumulated

Four Events That Detached the Name From the Organism

No single error created the sanghuang naming problem. A research literature settled on one binomial, taxonomy then moved that binomial into a different genus, a phylogeny found that the cultivated material was a third thing, and the supplement market never updated. The distance between the last two markers below is the gap a buyer is standing in.

1. 1996Literature

   The research program begins — under one name

   Indexed work on this mushroom starts appearing and, for the next twenty years, is published almost entirely under the binomial Phellinus linteus. Fifty studies in this library carry that nameplate.

2. 2016Taxonomy

   The genus splits in two

   Zhou and colleagues break the Inonotus linteus complex apart, erecting Sanghuangporus and Tropicoporus. Ten species move to Sanghuangporus, seven to Tropicoporus, and Phellinus linteus becomes Tropicoporus linteus.

3. 2016Taxonomy[1]

   Korea’s cultivars turn out to be something else

   A phylogeny of 74 strains finds that the sanghuang varieties formally registered in Korea — ASI 26046 (Corea sanghuang), 26114 (Boolro) and 26115 (HK 1-ho) — group with Sanghuangporus sanghuang rather than with Phellinus linteus.

4. 2019Taxonomy

   The new genus is filled in

   Multi-locus phylogenetic work recognises 13 species within Sanghuangporus and supports the genus as monophyletic, settling the shape of the group that Chinese sanghuang belongs to.

5. TodayMarketplace

   Labels are still one reclassification behind

   Products continue to read "Phellinus linteus", "Phellinus baumii", "Phellinus igniarius", or simply "sanghuang" — names that either predate the 2016 split or specify nothing at all.

A reclassification does not invalidate the research that preceded it. The 2016 split changed which name is correct, not what the experiments found. What it did change is the confidence with which a reader can assume that two papers sharing a binomial studied the same organism.

Zhou et al., Fungal Diversity, 2016; Han et al. [1]; Zhu et al., Frontiers in Microbiology, 2019

The Cancer Research: Broad, Mechanistically Coherent, and Entirely Preclinical

The most widely cited starting point of the modern research program is a 1999 paper reporting that polysaccharides isolated from P. linteus inhibited tumour growth and metastasis in mice.^[10] That result established polysaccharides as the primary anti-tumour compound class and set the direction for two decades of follow-up work.

What followed spans several tumour types. In colon cancer cells, a protein-bound polysaccharide induced G2/M phase arrest and apoptosis.^[9] In prostate cancer cells, extracts triggered apoptosis through more than one signalling route.^[8] In liver cancer, a 2024 mouse study reported reductions in tumour-promoting regulatory T cells and M2 macrophage polarisation via focal adhesion kinase signalling.^[11] And on the Sanghuangporus side, an alcohol extract of S. sanghuang suppressed lung cancer cell viability, migration and invasion, with an accompanying xenograft experiment in mice.^[3]

The breast cancer work is the most mechanistically comprehensive single study in the group. Sliva and colleagues found that P. linteus extract simultaneously inhibited proliferation and colony formation in highly invasive MDA-MB-231 cells, suppressed adhesion, migration and invasion, and blocked an early step in angiogenesis — all traced to inhibition of AKT signalling, with cell-cycle arrest mediated through upregulation of p27^Kip1.^[7] AKT is a central oncogenic node driving cancer cell survival and proliferation across many tumour types, so hitting three cancer-relevant behaviours through one pathway is a meaningful mechanistic result.

Two studies also examined sanghuang alongside conventional drugs rather than instead of them: extract combined with 5-fluorouracil inhibited breast cancer cell growth and induced autophagy,^[13] and P. linteus grown on germinated brown rice increased cetuximab sensitivity in KRAS-mutated colon cancer cells^[12] — a notable direction, since KRAS mutation normally predicts cetuximab resistance.

The unifying caveat is the same for every study above: these are cells in culture and tumours in mice. The detailed tumour-type breakdown, including the chemotherapy synergy findings, is covered in Sanghuang and Cancer: Research on Phellinus igniarius.

The Whole Evidence Estate

Two Lineages, One Market Name — and Where Each One’s Evidence Actually Stops

Supplements sold as “sanghuang” may contain either lineage. The column with the deep preclinical record is not the column Korea’s registered cultivars were found to belong to [1] — which is why the two are separated here rather than pooled.

Tropicoporus linteus

Published as Phellinus linteus · the research nameplate

Sanghuangporus sanghuang

Chinese tradition · and Korea’s registered cultivars [1]

1. Cell studies

   Human cancer cell lines in culture

   P. linteus · Substantial

   Breast, prostate, colon, liver, leukaemia and thyroid lines. Apoptosis, cell-cycle arrest, AKT and Wnt signalling, invasion and angiogenesis endpoints [7][8][9].

   S. sanghuang · Limited

   Lung cancer lines (A549, H1650) — viability, migration, invasion, STAT3 [3].

2. Animal studies

   Rodent tumour and xenograft models

   P. linteus · Substantial

   Tumour growth and metastasis inhibition in mice from 1999 onward [10]; hepatocellular carcinoma models through FAK, regulatory T cells and macrophage polarisation [11].

   S. sanghuang · Limited

   A single lung cancer xenograft model reported alongside the cell work [3].

3. Human — immune function

   Healthy adults, not patients

   P. linteus · Limited

   Two randomised placebo-controlled trials from one Korean group. The n=98 trial met its primary endpoint (NK cell activity, P < .05); nine secondary markers did not [4]. The n=30 study was an explicit pilot reporting trends only [5].

   S. sanghuang · None

   No trial has been published under a Sanghuangporus binomial.

4. Human — cancer outcomes

   Survival, recurrence, tumour response

   P. linteus · Limited

   One retrospective propensity-score-matched analysis in resected pancreatic cancer. Its authors attribute the survival difference to better chemotherapy adherence, not to direct anti-tumour activity [6].

   S. sanghuang · None

   None.

5. Randomised cancer trials

   The tier a treatment claim would require

   P. linteus · None

   None published.

   S. sanghuang · None

   None published.

Read down the columns rather than across the rows. The depth of the left column is what the phrase “extensively studied” refers to — and all of it is preclinical. The right column is the lineage a Korean-grown “sanghuang” product is most likely to contain. Neither column contains a randomised trial testing this mushroom as a cancer treatment.

Han et al. [1]; Sliva [2]; Wang et al. [3]; Ku et al. [4][5]; Lee et al. [6]

The Human Data: Three Datasets, None Testing Cancer Treatment

Sanghuang is frequently described as having "one human clinical trial." That undercounts it and mischaracterises what was done. There are three human datasets, and the distinctions between them matter.

The two randomised trials. Both were published in 2022, in the same journal, by the same Korean research group — Ku and Kang appear on both papers, which makes them two reports from one program rather than two independent replications.

The larger trial randomised 98 participants to 1,000 mg of P. linteus extract or 1,000 mg of dextrin daily for eight weeks. Natural killer cell activity, the primary endpoint, increased significantly in the extract group versus placebo. Nine secondary markers — TNF-α, IFN-γ, IL-1β, IL-2, IL-6, IL-12, IgG1, IgG2 and IgM — showed no significant changes, though the authors noted a tendency toward improvement. No adverse effects on liver or renal function were observed.^[4]

The second was an explicit pilot: 30 participants across three arms (1,000 mg extract, 2,000 mg extract, or placebo), also for eight weeks. Natural killer cell activity and IL-6 tended to improve in the 1,000 mg group; immunoglobulin levels did not change significantly. The paper's stated purpose was to secure evidence for a future full-scale trial.^[5]

Both trials enrolled healthy adults. Neither measured a cancer outcome.

The oncology dataset. Separately, a retrospective analysis at a Korean hospital examined 217 patients who underwent curative resection for pancreatic ductal adenocarcinoma, 161 of whom received adjuvant treatment. Using propensity score matching, the authors found that P. linteus use was the only significant predictor of completing adjuvant chemotherapy, and that disease-free and overall survival were higher in the group that used it.^[6]

That sounds stronger than it is, and the authors themselves are careful about why. This is a retrospective observational analysis, not a randomised trial. Propensity matching reduces measured confounding but cannot eliminate the unmeasured kind — patients who choose and can afford a supplement often differ systematically from those who do not. Most importantly, the paper's own proposed mechanism is not direct anti-tumour activity: it is that the supplement was associated with lower chemotherapy toxicity, letting patients complete treatment they would otherwise have abandoned. Completing chemotherapy is a well-established survival determinant on its own.

Where sanghuang's evidence actually sits

1. Cell studiescompleted

   Extensive across both lineages — apoptosis, cell-cycle arrest, angiogenesis and invasion endpoints in breast, prostate, colon, liver and lung cancer lines.

2. Animal studiescompleted

   Multiple rodent models, including xenograft work for both Phellinus linteus and Sanghuangporus sanghuang extracts.

3. Case reportscompleted

   A small number of uncontrolled tumour regression reports noted in the 2010 review — the weakest form of human evidence.

4. Small human trialscurrent

   Two randomised placebo-controlled immune-function trials (n=98 and n=30) from one research group, plus one retrospective propensity-score-matched analysis in 217 pancreatic cancer patients.

5. Large RCTsmissing

   None. No adequately powered randomised trial has tested this mushroom against a cancer endpoint.

6. Meta-analysesmissing

   None — there is no pool of comparable clinical trials to synthesise.

The preclinical base is broad and the mechanistic story is coherent, but human testing stops at two modest immune-function trials and one observational oncology analysis. Nothing here demonstrates that sanghuang treats cancer in people.

Sliva, Experimental and Therapeutic Medicine, 2010; Ku et al., Medicine, 2022; Lee et al., Integrative Cancer Therapies, 2019

Efficacy

Sanghuang is a proven cancer treatment

The claim

“Sanghuang is Korea's cancer-fighting mushroom, with decades of research proving it kills cancer cells and shrinks tumours.”

The preclinical literature is genuinely large and the findings are genuinely positive. Marketing quotes those findings accurately while omitting the model system — 'inhibited tumour growth' is true of mice, and reads as though it were true of patients.

What research shows

Misleading

Every cancer finding attributed to sanghuang comes from cell culture or animal models. The only randomised human trials measured immune markers in healthy adults, and the single oncology dataset is a retrospective analysis whose authors attribute the survival difference to improved chemotherapy adherence rather than to direct anti-tumour activity.

This is not a debunking. The mechanistic work is serious, reproducible across laboratories, and biologically plausible — AKT inhibition, apoptosis induction and anti-angiogenic activity are real findings. The claim that fails is not 'sanghuang does something' but 'sanghuang treats cancer in people,' which has never been tested.

Sliva, Experimental and Therapeutic Medicine, 2010; Ku et al., Medicine, 2022; Lee et al., Integrative Cancer Therapies, 2019

Safety · high

Sanghuang is not a cancer treatment, and it is not inert around one

The 'cancer-fighting mushroom' framing creates two distinct risks. The first is substitution — delaying or declining evidence-based oncology care in favour of a supplement with no randomised efficacy data against any cancer. The second is interaction: sanghuang's documented activity is immunomodulatory, and it has been studied specifically alongside chemotherapy agents including 5-fluorouracil and cetuximab in laboratory models. Whatever those interactions mean clinically has not been characterised in patients.

Treat this literature as biology rather than as a treatment protocol. The established human safety envelope is narrow and specific: 1,000 mg daily for eight weeks in 98 healthy adults, with no adverse effects reported on liver or renal function, and up to 2,000 mg daily in a 30-participant pilot. That is not evidence of safety in cancer patients, in people on immunosuppressive or immune-modulating therapy, or over longer periods.

Particularly relevant for: Anyone undergoing or considering cancer treatment; people taking immunosuppressants or immunotherapy; people with autoimmune conditions, for whom immune-stimulating supplements warrant particular caution

Discuss any mushroom supplement with your oncology team before starting it, and tell them the exact species and product. Never delay or substitute conventional treatment. This article is educational and not medical advice.

Navigating Sanghuang Supplements: What to Look For

Given everything above, label reading for this mushroom is unusually consequential.

Species identity is the first filter. "Sanghuang" alone is a category name and tells you nothing — it is compatible with at least two genera. Look for a binomial: Sanghuangporus sanghuang (or another Sanghuangporus species), or Phellinus linteus / Tropicoporus linteus. Be aware that even a P. linteus label is not decisive, since that is the historical research nameplate rather than a guarantee of current identity, and Korea's own registered cultivars were placed elsewhere by phylogeny.^[1]

Extract type determines which compound class you are actually getting. Water-based extraction concentrates polysaccharides — the fraction carrying most of the immune and anti-tumour findings, including the 1999 mouse work and the compounds used in the human trials. Ethanol and other alcohol extractions pull more of the phenolic compounds, hispidin and hispolon. These are different chemistries with different research behind them, and "full-spectrum" claims should specify how both were obtained.

Substrate can change the product. Several studies used P. linteus grown on germinated brown rice rather than a standard substrate, and the cetuximab-sensitising work was conducted on that specific preparation.^[12] Commercial products rarely disclose substrate, and where they do, no standard exists for relating it to compound content.

Dose standardisation is largely absent. Most products do not declare polysaccharide content — the usual benchmark for medicinal mushroom supplements — and essentially none declare hispidin or hispolon. Without standardisation, batch-to-batch variation in active compound concentration should be assumed. The one figure with human grounding is the trial dose: 1,000 mg of extract daily, of a specific preparation, for eight weeks, measured against immune markers rather than any disease endpoint.^[4]

Sanghuang sits within the broader emerging and specialty mushroom category explored at What Is Agarikon?.

The Bottom Line

Sanghuang is a traditional East Asian category name for bracket fungi now divided between the genera Sanghuangporus and Tropicoporus. Nearly all English-language research was published under the name Phellinus linteus, reassigned in 2016 to Tropicoporus linteus — while a 2016 phylogeny of 74 strains found that Korea's formally registered sanghuang cultivars group with Sanghuangporus sanghuang instead, meaning the research nameplate and the cultivated organism can diverge. The preclinical anti-cancer record is broad and mechanistically coherent, covering breast, prostate, colon, liver and lung models through apoptosis induction, AKT inhibition, angiogenesis blockade and metastasis suppression, with two studies examining synergy alongside 5-fluorouracil and cetuximab. Human evidence consists of three datasets: two randomised immune-function trials in healthy adults from a single Korean group, of which only the larger (n=98) met its primary endpoint of natural killer cell activity while all nine secondary markers did not, and one retrospective propensity-score-matched analysis in pancreatic cancer patients whose authors attribute the survival difference to improved chemotherapy adherence. No randomised trial has tested sanghuang as a cancer treatment. Species identity is the key label indicator, and "sanghuang" alone specifies nothing.

Frequently Asked Questions

What is sanghuang mushroom?

Sanghuang is a traditional Korean and Chinese name for a group of woody bracket fungi that grow on mulberry, fig and other broadleaf trees. It is not a species name. The organisms it refers to are now divided between the genera Sanghuangporus and Tropicoporus — the latter containing the mushroom published throughout the research literature as Phellinus linteus. The mushrooms have been used in East Asian medicine for centuries and have a substantial modern research base, though that research is almost entirely preclinical.

Is sanghuang the same as meshima?

Partly. Meshima is the Japanese supplement trade name for the mushroom published in the research literature as Phellinus linteus, reassigned in 2016 to Tropicoporus linteus. "Sanghuang" is a broader traditional category that can refer to that organism or to mulberry-associated Sanghuangporus species. Complicating things further, a 2016 phylogenetic study found Korea's registered sanghuang cultivars group with Sanghuangporus sanghuang rather than with P. linteus, so the two terms overlap without being equivalent.

What is sanghuang used for?

Traditional East Asian medicine used sanghuang for immunity, inflammation and tumours. Modern research has examined it primarily for anti-cancer activity across breast, prostate, colon, liver and lung models in cells and animals, and for immune function in humans. Two randomised trials in healthy adults measured immune markers, with natural killer cell activity improving significantly in the larger one. It is not an approved treatment for any condition, and all cancer-specific evidence remains preclinical. This is not medical advice.

Does sanghuang fight cancer?

In cell cultures and animal models, extracts show anti-tumour activity across several cancer types through apoptosis induction, cell-cycle arrest, AKT pathway inhibition, angiogenesis blockade and metastasis suppression. Two laboratory studies also found it enhanced the effects of 5-fluorouracil and cetuximab. In people, this has never been tested: no randomised trial has measured whether sanghuang affects any cancer outcome. The single oncology dataset is a retrospective analysis in pancreatic cancer patients whose authors attribute the survival difference to patients completing more of their chemotherapy, not to the mushroom attacking tumours. Sanghuang is not an approved cancer treatment, and it should not replace or delay oncology care.

What are the benefits of sanghuang mushroom?

The best-supported human finding is a modest one: in a 98-participant randomised trial, eight weeks of 1,000 mg daily extract significantly improved natural killer cell activity versus placebo, while nine other immune markers showed no significant change. A 30-participant pilot found trends in the same direction without reaching significance. Everything else — the anti-cancer, anti-inflammatory and liver-related findings — comes from cells and animals. Traditional use attributes broader benefits that modern research has not tested in people.

How do you take sanghuang mushroom?

The only human-grounded dose comes from the Korean trials: 1,000 mg of a specific P. linteus extract daily for eight weeks, with a pilot also testing 2,000 mg. Those trials measured immune markers in healthy adults, so the dose does not transfer to any disease indication. Available forms include dried powder, water extracts (which concentrate polysaccharides) and ethanol extracts (which concentrate hispidin and hispolon). Look for a product that names an actual species rather than just "sanghuang," and ideally declares polysaccharide content. If you have a health condition or are undergoing cancer treatment, discuss it with your clinician first — this is not medical advice.

Sources & References

1. 1RTHM-00783·Han, Jae-Gu et al. (2016). “Species identity of Phellinus linteus (sanghuang) extensively used as a medicinal mushroom in Korea..” Journal of microbiology (Seoul.Study breakdown →PubMed →↩
2. 2RTHM-00364·Sliva, Daniel (2010). “Medicinal mushroom Phellinus linteus as an alternative cancer therapy..” Experimental and therapeutic medicine.Study breakdown →PubMed →↩
3. 3RTHM-01817·Wang, Weike et al. (2023). “Sanghuangporus sanghuang extract inhibits the proliferation and invasion of lung cancer cells in vitro and in vivo..” Nutrition research and practice.Study breakdown →PubMed →↩
4. 4RTHM-01556·Ku, Yong Ho et al. (2022). “Effects of Phellinus linteus extract on immunity improvement: A CONSORT-randomized, double-blinded, placebo-controlled trial..” Medicine.Study breakdown →PubMed →↩
5. 5RTHM-01555·Ku, Yong Ho et al. (2022). “Efficacy of Phellinus linteus extract on immunity enhancement: A CONSORT-randomized, double-blind, placebo-controlled pilot trial..” Medicine.Study breakdown →PubMed →↩
6. 6RTHM-01082·Lee, Sung Hwan et al. (2019). “Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity Score-Matched Analysis..” Integrative cancer therapies.Study breakdown →PubMed →↩
7. 7RTHM-00271·Sliva, D et al. (2008). “Phellinus linteus Extract in Breast-Cancer Cell Models: What This 2008 Study Actually Found.” British journal of cancer.Study breakdown →PubMed →↩
8. 8RTHM-00240·Zhu, T et al. (2007). “Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells..” British journal of cancer.Study breakdown →PubMed →↩
9. 9RTHM-00140·Li, Ge et al. (2004). “Protein-bound polysaccharide from Phellinus linteus induces G2/M phase arrest and apoptosis in SW480 human colon cancer cells..” Cancer letters.Study breakdown →PubMed →↩
10. 10RTHM-00065·Han, S B et al. (1999). “The inhibitory effect of polysaccharides isolated from Phellinus linteus on tumor growth and metastasis..” Immunopharmacology.Study breakdown →PubMed →↩
11. 11RTHM-01867·Chen, Feihua et al. (2024). “Phellinus linteus activates Treg cells via FAK to promote M2 macrophage polarization in hepatocellular carcinoma..” Cancer immunology.Study breakdown →PubMed →↩
12. 12RTHM-00904·Park, Hye-Jin et al. (2017). “Phellinus linteus Grown on Germinated Brown Rice Increases Cetuximab Sensitivity of KRAS-Mutated Colon Cancer..” International journal of molecular sciences.Study breakdown →PubMed →↩
13. 13RTHM-00710·Lee, Wen-Ying et al. (2015). “Phellinus linteus extract induces autophagy and synergizes with 5-fluorouracil to inhibit breast cancer cell growth..” Nutrition and cancer.Study breakdown →PubMed →↩